Athira Pharma (NASDAQ:ATHA) Downgraded by BTIG Research to Neutral

BTIG Research lowered shares of Athira Pharma (NASDAQ:ATHA) from a buy rating to a neutral rating in a report published on Wednesday morning, MarketBeat Ratings reports.

ATHA has been the topic of several other reports. JMP Securities lowered shares of Athira Pharma from an outperform rating to a market perform rating in a report on Wednesday. Rodman & Renshaw initiated coverage on Athira Pharma in a research report on Monday, August 19th. They set a buy rating and a $22.00 target price on the stock.

Athira Pharma Price Performance

Shares of ATHA stock opened at $0.61 on Wednesday. The stock’s 50-day moving average is $3.05 and its 200 day moving average is $2.78. Athira Pharma has a 1-year low of $0.60 and a 1-year high of $4.30. The company has a market cap of $23.40 million, a P/E ratio of -0.20 and a beta of 2.90.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.05. On average, analysts anticipate that Athira Pharma will post -2.56 EPS for the current year.

Insider Buying and Selling at Athira Pharma

In related news, Director Kelly A. Romano acquired 15,000 shares of the stock in a transaction dated Friday, June 21st. The stock was acquired at an average cost of $2.26 per share, for a total transaction of $33,900.00. Following the completion of the purchase, the director now owns 53,315 shares of the company’s stock, valued at approximately $120,491.90. The purchase was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Kelly A. Romano acquired 15,000 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were acquired at an average cost of $2.26 per share, with a total value of $33,900.00. Following the completion of the acquisition, the director now owns 53,315 shares of the company’s stock, valued at $120,491.90. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Kelly A. Romano bought 27,400 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were purchased at an average cost of $2.42 per share, with a total value of $66,308.00. Following the acquisition, the director now directly owns 80,715 shares of the company’s stock, valued at $195,330.30. The disclosure for this purchase can be found here. 19.80% of the stock is currently owned by company insiders.

Institutional Trading of Athira Pharma

Several large investors have recently made changes to their positions in the business. Rothschild Investment LLC acquired a new position in Athira Pharma during the second quarter valued at $34,000. Private Advisor Group LLC purchased a new position in shares of Athira Pharma during the 4th quarter valued at about $32,000. Mirador Capital Partners LP purchased a new position in shares of Athira Pharma during the 1st quarter valued at about $57,000. XTX Topco Ltd acquired a new position in shares of Athira Pharma in the 2nd quarter valued at about $60,000. Finally, Invst LLC purchased a new stake in shares of Athira Pharma in the second quarter worth about $68,000. 57.12% of the stock is owned by hedge funds and other institutional investors.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.